These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9284696)

  • 1. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
    Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
    J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
    Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
    Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of early postmenopausal bone loss with cyclical etidronate.
    Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
    J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
    Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
    N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty.
    Yamaguchi K; Masuhara K; Yamasaki S; Fuji T; Seino Y
    Bone; 2004 Jul; 35(1):217-23. PubMed ID: 15207760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
    Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
    Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.
    Pouilles JM; Tremollieres F; Roux C; Sebert JL; Alexandre C; Goldberg D; Treves R; Khalifa P; Duntze P; Horlait S; Delmas P; Kuntz D
    Osteoporos Int; 1997; 7(3):213-8. PubMed ID: 9205633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
    Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
    Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.